Kyprolis RSD Michael Kacer and Perry Monaco to be replaced by OBU management

Quote
anonymous said:
Amgen and honorable don't belong in the same sentence. By August 2016, or S2 OBU will have to be trained on Kyprolis as there will be a lack of critical mass in legacy Onyx leadership in sales. As one poster mentioned, it's just a matter of time. It might have taken 3 years, but Jensen will get his wish of having Kyprolis and whatever Onyx reps are left. OBU leadership will likely drive them out and put in inferior reps who they choose in their place. OBU will then become PCP metric driven as new reps fail to deliver and more and more big pharma metrics will be developed as Amgen's future is pegged toward Kyprolis and Repatha growth when established products no longer grow, even with 3 times a year 5.0% price increases.
Click to expand...

Truth
 








































anonymous said:
Why is this funny? I am inventiv/Amgen contract rep looking to gain oncology experience so I can work at other oncology companies later. I also hope these subpar Onyx reps are fired to give us hard working reps in other BUs a chance at Kyprolis.
Click to expand...

First INBU reps wanted Kyprolis, now inVentiv reps think they should be kicking legacy Onyx reps out! If you are a former onyx rep, this is a sign that you should leave Amgen if you haven't already. Clearly no one at Amgen wants you here and now even contract reps have no respect for you.
 








































Top Bottom
Back
Quote